Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA-2: LND101 FMT + ICB + Chemotherapy in Advanced NSCLC
NCT07890493Phase 2Not yet recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2026
- Primary completion
- Dec 2030
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Standard of Care ICB + Chemotherapy with FMT + Standard of care ICB + Chemotherapy (2 arms). Primary endpoint: Progression-Free Survival at 4 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
LND101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07890493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890493.